Accessibility
Our Company
About Us
Our Team
Board of Directors
Scientific Advisory Board
Contact Us
Technology & Innovation
Riboswitch in-vivo Delivery Platform
Next-Generation Vector Optimization
End-to-end Manufacturing Ecosystem
Posters & Publications
Programs & Pipeline
Pipeline
Parkinson’s Disease
Xerostomia
AIPL1 Retinal Dystrophy
Patients & Families
Commitment to Patients
Parkinson’s Disease
Radiation-Induced Xerostomia
Inherited Retinal Disease
Rare Diseases
Investors & Media
Overview
News Releases
Events & Presentations
Stock Information
Corporate Governance
Financial Information
Investor Resources
Join Our Team
Development and efficacy assessment of AAV2/8-hG1.7p.coCNGA3, a
CNGA3
gene therapy vector.